FDA has granted Shorla Oncology’s second FDA acceptance for a New Drug Application (NDA) for SH-201, the first palatable oral liquid form of a chemotherapeutic agent designed to treat leukemia and other cancers.
Read more at: Article
FDA has granted Shorla Oncology’s second FDA acceptance for a New Drug Application (NDA) for SH-201, the first palatable oral liquid form of a chemotherapeutic agent designed to treat leukemia and other cancers.
Read more at: Article
